On August 31, 2026 the White House announced Most-Favored-Nation drug-pricing agreements with nine more manufacturers: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. That takes the total to 26, which the administration outlines that it covers 89% of the branded drug market.
Read the fact sheet and the eight company releases side by side, though, and you learn more than either gives you on its own. The two sides are advertising different halves of the same bargain.
1. The administration and the companies emphasize opposite sides of the deal
The fact sheet does not mention Section 232 pharmaceutical tariffs once. But tariff treatment is all over the company releases: BeOne secured an outright exemption, UCB says it will not be subject to 232 tariffs on its current products, Kyowa Kirin agreed a deferral with the Department of Commerce, Sun Pharma won a delay of more than two years, and CSL cites additional certainty on its 232 exposure. The same asymmetry applies to protection from future pricing mandates, which UCB and BridgeBio both claim and the White House never mentions. So the public record spells out what the companies gave up, and stays vague about what they got for it.
2. Medicaid is the delivery mechanism, which is narrower than “lower drug prices”
Almost every commitment runs through Medicaid, mostly via the GENEROUS model: BeOne, BridgeBio, Kyowa Kirin and UCB participate, and Teva would ‘if it signs’. Sun Pharma extends MFN pricing to state Medicaid programs; Astellas will lower Medicaid prices. Two companies do go further. CSL will price newly launched therapies at developed-country levels for all U.S. payers, and BridgeBio will keep Attruby in Medicare Part D without future pricing mandates. Both look like outliers rather than the template.
3. This tranche is the middle of the market, and the program is close to saturation
The White House itself describes the nine as mid-sized pharmaceutical companies. The 17 majors were signed in earlier rounds, beginning with Pfizer in September 2025. At 26 agreements covering 89% of branded volume, there is not much runway left, so the story shifts from expansion to execution.
4. The economics are asserted at portfolio level and undisclosed at product level
Every company release states that terms are confidential. Not one discloses a benchmark, a covered-product list, a discount level, a contract duration or an expected financial impact; CSL goes only as far as saying it anticipates no material impact in fiscal 2027. Against that silence, every public number is an aggregate: at least $19.6 billion of near-term U.S. manufacturing investment, “billions of dollars” in Medicaid savings, and a Council of Economic Advisers estimate of $600 billion over the next decade. None of them comes with a published methodology.
Tellingly, the hardest numbers anywhere in the set are the supply-chain donations to the Strategic Active Pharmaceutical Ingredients Reserve: 163 tons of levetiracetam from UCB, 71.4 tons of clindamycin and 6.75 tons of doxycycline from Sun Pharma, 45 metric tons of metronidazole and 4.8 tons of amlodipine from Teva, and 25 kg of tacrolimus from Astellas.
One caveat on the roster
The fact sheet counts Teva among the nine and lists it again among all 26 manufacturers with agreements. Teva’s own release is titled “Intent to Reach Agreement”, says the company remains in active discussions, and describes its terms as applying “if an agreement is reached.” The roster is presented more firmly than at least one participant describes it.
What to watch
The scope of the policy is now clear: Medicaid pricing, pricing of future launches, U.S. onshoring, Section 232 tariff treatment and supply-chain resilience. What remains unclear is the economics: which products are covered, which foreign prices serve as benchmarks, how large the discounts are, and for how long. Those answers will emerge in implementation, regulatory filings and earnings calls, not in press releases.
